Schmid John P.
Insider CIK 1478916 · XERS Director · TSRX Chief Financial Officer · ANAB Director · ASPX Chief Financial Officer · NEOS Director · PSTX Director · DSGN Director · BLSM Director · XERS Director · BBOT · TRAX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-10 | 6,000 | $16.00 | $96.0K | 6,000 | SEC↗ |
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-10 | 6,000 | $16.00 | $96.0K | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise deriv | 2026-06-15 | 2026-06-17 | 6,030 | — | $0 | 0 | SEC↗ |
| TRAX First Tracks Biotherapeuti | M Exercise deriv | 2026-06-15 | 2026-06-17 | 6,030 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise | 2026-06-15 | 2026-06-17 | 6,030 | — | $0 | 37,652 | SEC↗ |
| TRAX First Tracks Biotherapeuti | M Exercise | 2026-06-15 | 2026-06-17 | 6,030 | — | $0 | 37,652 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-05-12 | 2026-05-14 | 42,000 | — | $0 | 42,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-05-12 | 2026-05-14 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-05-12 | 2026-06-12 | 7,000 | — | $0 | 7,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-05-12 | 2026-06-12 | 2,500 | — | $0 | 2,500 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 6,030 | — | $0 | 6,030 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 5,500 | — | $0 | 5,500 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 10,600 | — | $0 | 10,600 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 4,000 | — | $0 | 4,000 | SEC↗ |
| TRAX First Tracks Biotherapeuti | A Award deriv | 2026-04-20 | 2026-04-22 | 9,200 | — | $0 | 9,200 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 10,600 | — | $0 | 10,600 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 10,600 | — | $0 | 10,600 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 9,200 | — | $0 | 9,200 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 9,200 | — | $0 | 9,200 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 5,500 | — | $0 | 5,500 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 5,500 | — | $0 | 5,500 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| ANAB ANAPTYSBIO, INC | D To issuer deriv | 2026-04-20 | 2026-04-22 | 16,510 | — | $0 | 16,510 | SEC↗ |
| ANAB ANAPTYSBIO, INC | S Sale | 2026-03-30 | 2026-04-01 | 522 | $57.40 | $30.0K | 31,622 | SEC↗ |
| ANAB ANAPTYSBIO, INC | S Sale | 2026-03-30 | 2026-04-01 | 7,527 | $56.70 | $426.8K | 32,144 | SEC↗ |
| ANAB ANAPTYSBIO, INC | S Sale | 2026-03-30 | 2026-04-01 | 12,596 | $55.71 | $701.7K | 39,671 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-01-06 | 2026-01-08 | 5,500 | — | $0 | 5,500 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2026-01-06 | 2026-01-08 | 4,000 | — | $0 | 4,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2025-12-23 | 2025-12-23 | 11,068 | $51.00 | $564.5K | 0 | SEC↗ |
| BBOT BridgeBio Oncology Therape | M Exercise deriv | 2025-08-11 | 2025-08-11 | 30,000 | — | $0 | 0 | SEC↗ |
| BBOT BridgeBio Oncology Therape | M Exercise | 2025-08-11 | 2025-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise deriv | 2025-06-15 | 2025-06-17 | 6,030 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise | 2025-06-15 | 2025-06-17 | 6,030 | — | $0 | 52,267 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2025-06-10 | 2025-06-12 | 19,000 | — | $0 | 19,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | J Other | 2025-03-25 | 2025-03-27 | 11,068 | $18.18 | $201.2K | 11,068 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise deriv | 2025-01-13 | 2025-01-15 | 21,692 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise deriv | 2025-01-13 | 2025-01-15 | 20,645 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise | 2025-01-13 | 2025-01-15 | 21,692 | $4.55 | $98.7K | 25,592 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise | 2025-01-13 | 2025-01-15 | 20,645 | $8.54 | $176.3K | 46,237 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 27,350 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 27,350 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 16,038 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 20,000 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 20,000 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 25,833 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 32,076 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | D To issuer deriv | 2025-01-08 | 2025-01-08 | 28,500 | — | $0 | 0 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | U Tender | 2025-01-08 | 2025-01-08 | 58,950 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2025-01-07 | 2025-01-07 | 16,510 | — | $0 | 16,510 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2025-01-07 | 2025-01-07 | 6,030 | — | $0 | 6,030 | SEC↗ |
| XERS Xeris Biopharma Holdings, | P Buy | 2024-08-12 | 2024-08-13 | 4,515 | $2.25 | $10.2K | 25,200 | SEC↗ |
| XERS Xeris Biopharma Holdings, | P Buy | 2024-08-09 | 2024-08-12 | 4,285 | $2.37 | $10.2K | 20,685 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2024-06-17 | 2024-06-18 | 27,350 | — | $0 | 27,350 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award | 2024-06-17 | 2024-06-18 | 19,650 | — | $0 | 58,950 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise deriv | 2024-06-15 | 2024-06-18 | 3,900 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | M Exercise | 2024-06-15 | 2024-06-18 | 3,900 | — | $0 | 3,900 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-17 | 19,000 | — | $0 | 19,000 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award | 2024-06-05 | 2024-06-05 | 50,000 | — | $0 | 113,159 | SEC↗ |
| XERS Xeris Biopharma Holdings, | P Buy | 2024-05-10 | 2024-05-10 | 5,400 | $1.91 | $10.3K | 16,400 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2024-03-25 | 2024-03-25 | 17,809 | $3.74 | $66.6K | 26,965 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2024-03-22 | 2024-03-25 | 9,156 | $3.62 | $33.1K | 9,156 | SEC↗ |
| XERS Xeris Biopharma Holdings, | P Buy | 2024-03-14 | 2024-03-14 | 4,500 | $2.16 | $9.7K | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2024-01-03 | 2024-01-05 | 6,030 | — | $0 | 6,030 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2024-01-03 | 2024-01-05 | 16,510 | — | $0 | 16,510 | SEC↗ |
| XERS Xeris Biopharma Holdings, | P Buy | 2023-11-16 | 2023-11-17 | 6,500 | $1.51 | $9.8K | 6,500 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2023-06-15 | 2023-06-16 | 27,350 | — | $0 | 27,350 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award | 2023-06-15 | 2023-06-16 | 19,650 | — | $0 | 39,300 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award | 2023-06-07 | 2023-06-07 | 42,500 | — | $0 | 63,159 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 3,900 | — | $0 | 3,900 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 10,600 | — | $0 | 10,600 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2022-06-16 | 2022-06-16 | 28,500 | — | $0 | 28,500 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award | 2022-06-16 | 2022-06-16 | 19,650 | — | $0 | 19,650 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2022-06-15 | 2022-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award deriv | 2022-06-08 | 2022-06-09 | 25,000 | — | $0 | 25,000 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award | 2022-06-08 | 2022-06-09 | 15,000 | — | $0 | 20,659 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2022-02-10 | 2022-02-14 | 9,200 | — | $0 | 9,200 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | D To issuer deriv | 2021-10-05 | 2021-10-05 | 20,000 | — | $0 | 0 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | D To issuer deriv | 2021-10-05 | 2021-10-05 | 25,220 | — | $0 | 0 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | D To issuer deriv | 2021-10-05 | 2021-10-05 | 11,228 | — | $0 | 0 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | D To issuer deriv | 2021-10-05 | 2021-10-05 | 11,228 | — | $0 | 0 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award deriv | 2021-10-05 | 2021-10-05 | 11,228 | — | $0 | 11,228 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award deriv | 2021-10-05 | 2021-10-05 | 11,228 | — | $0 | 11,228 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award deriv | 2021-10-05 | 2021-10-05 | 25,220 | — | $0 | 25,220 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award deriv | 2021-10-05 | 2021-10-05 | 20,000 | — | $0 | 20,000 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | D To issuer | 2021-10-05 | 2021-10-05 | 5,659 | — | $0 | 0 | SEC↗ |
| XERS Xeris Biopharma Holdings, | A Award | 2021-10-05 | 2021-10-05 | 5,659 | — | $0 | 5,659 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2021-07-23 | 2021-07-26 | 25,833 | — | $0 | 25,833 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2021-06-16 | 2021-06-17 | 20,000 | — | $0 | 20,000 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | A Award deriv | 2021-06-08 | 2021-06-08 | 11,228 | — | $0 | 11,228 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2021-03-25 | 2021-03-29 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer deriv | 2021-03-19 | 2021-03-19 | 22,756 | — | $0 | 0 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer deriv | 2021-03-19 | 2021-03-19 | 46,907 | — | $0 | 0 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer deriv | 2021-03-19 | 2021-03-19 | 18,322 | — | $0 | 0 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer deriv | 2021-03-19 | 2021-03-19 | 14,777 | — | $0 | 0 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer deriv | 2021-03-19 | 2021-03-19 | 12,500 | — | $0 | 0 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | D To issuer | 2021-03-19 | 2021-03-19 | 23,453 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2021-02-10 | 2021-02-12 | 11,000 | — | $0 | 11,000 | SEC↗ |
| PSTX Poseida Therapeutics, Inc. | A Award deriv | 2020-07-09 | 2020-07-13 | 20,000 | — | $0 | 20,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | A Award | 2020-06-10 | 2020-06-11 | 23,453 | — | $0 | 23,453 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | A Award deriv | 2020-06-04 | 2020-06-04 | 11,228 | — | $0 | 11,228 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2020-02-12 | 2020-02-13 | 11,000 | — | $0 | 11,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | A Award deriv | 2019-06-13 | 2019-06-17 | 46,907 | — | $0 | 46,907 | SEC↗ |
| XERS XERIS PHARMACEUTICALS INC | A Award deriv | 2019-02-27 | 2019-03-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2019-02-08 | 2019-02-11 | 6,000 | — | $0 | 6,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | A Award deriv | 2018-07-02 | 2018-07-03 | 22,756 | — | $0 | 22,756 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2018-02-02 | 2018-02-06 | 6,000 | — | $0 | 6,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | A Award deriv | 2017-07-03 | 2017-07-05 | 18,322 | — | $0 | 18,322 | SEC↗ |
| ANAB ANAPTYSBIO INC | A Award deriv | 2017-02-24 | 2017-02-28 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NEOS Neos Therapeutics, Inc. | A Award deriv | 2016-07-01 | 2016-07-05 | 14,777 | — | $0 | 14,777 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 30,000 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 15,000 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 59,026 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | U Tender | 2015-05-05 | 2015-05-06 | 144,444 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | A Award deriv | 2015-02-02 | 2015-02-04 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | A Award deriv | 2015-02-02 | 2015-02-04 | 30,000 | — | $0 | 30,000 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer deriv | 2013-09-11 | 2013-09-13 | 28,720 | $12.21 | $350.7K | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer deriv | 2013-09-11 | 2013-09-13 | 8,138 | $12.21 | $99.4K | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer deriv | 2013-09-11 | 2013-09-13 | 85,000 | $8.70 | $739.5K | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer deriv | 2013-09-11 | 2013-09-13 | 75,000 | $10.00 | $750.0K | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer deriv | 2013-09-11 | 2013-09-13 | 140,000 | $7.37 | $1.03M | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | D To issuer | 2013-09-11 | 2013-09-13 | 107,639 | — | $0 | 0 | SEC↗ |
| TSRX Trius Therapeutics Inc | A Award deriv | 2013-03-07 | 2013-03-11 | 140,000 | — | $0 | 140,000 | SEC↗ |
| TSRX Trius Therapeutics Inc | S Sale | 2012-06-22 | 2012-06-25 | 1,800 | $6.00 | $10.8K | 107,639 | SEC↗ |
| TSRX Trius Therapeutics Inc | M Exercise deriv | 2012-03-27 | 2012-03-28 | 5,000 | — | $0 | 28,720 | SEC↗ |
| TSRX Trius Therapeutics Inc | M Exercise | 2012-03-27 | 2012-03-28 | 5,000 | $1.29 | $6.5K | 109,439 | SEC↗ |
| TSRX Trius Therapeutics Inc | A Award deriv | 2012-03-08 | 2012-03-12 | 85,000 | — | $0 | 85,000 | SEC↗ |
| TSRX Trius Therapeutics Inc | S Sale | 2012-03-01 | 2012-03-02 | 500 | $5.04 | $2.5K | 104,439 | SEC↗ |
| TSRX Trius Therapeutics Inc | S Sale | 2012-02-02 | 2012-02-06 | 500 | $5.63 | $2.8K | 104,939 | SEC↗ |
| TSRX Trius Therapeutics Inc | S Sale | 2012-01-03 | 2012-01-04 | 700 | $7.28 | $5.1K | 105,439 | SEC↗ |